TY - JOUR
T1 - Three-dimensional analysis of isolated hexosaminidase-altered aberrant crypts from colons of 1,2-dimethylhydrazine-treated rats
AU - Tsukamoto, Tetsuya
AU - Sakai, Hiroki
AU - Hirata, Akihiro
AU - Fukami, Hiroko
AU - Tatematsu, Masae
N1 - Funding Information:
We thank Dr. Malcolm Moore for valuable discussion. This work was supported in part by a Grant-in-Aid for Cancer Research from the Ministry of Health, Labour and Welfare, Japan, and a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan.
PY - 2006/3/6
Y1 - 2006/3/6
N2 - Aberrant crypt foci, consisting of morphologically irregular crypts, are thought to be precancerous lesions for colorectal cancers. For analysis of individual crypts, F344 rats were administered weekly subcutaneous injections of 1,2-dimethylhydrazine ten times and sacrificed at experimental weeks 10 and 20 with 5-bromo-2′-deoxyuridine (BrdU) incorporation 1 h before the sacrifice. Isolated colonic crypts were classified into hexosaminidase-altered aberrant crypts (HAACs) and hexosaminidase-preserved normal-appearing crypts (HPNCs) and stereopaired images (tilt angle, 6°) were taken with a scanning electron microscope for three-dimensional analyses. While HPNCs showed symmetrical fission at the base, HAACs exhibited abnormal budding in the middle of the crypt body. At week 10, average BrdU labeled cells per crypt for DMH-treated HPNCs and HAACs were 4.9±1.0 and 18.7±2.2 (P<0.0001), respectively, while the value for non-treated control crypts was 14.7±0.8/crypt. BrdU-positive cell numbers per unit crypt length (100 μm) in HPNCs and HAACs were 1.75±0.37 and 5.99±0.70 (P<0.0001), respectively, while that for the control was 6.65±0.35 (P<0.02 vs. HAAC). At the 20-week time point, the numbers per crypt were 4.0±0.8, 10.1±1.6, and 27.4±2.4, respectively, the control value being significantly higher than the others (P<0.0001). The figures per unit length were 1.72±0.35, 2.92±0.42, and 13.39±1.11 (P<0.0001 vs. HAAC and HPNC), respectively. BrdU incorporating cells were distributed in the bottom third of the crypt columns in HAACs, but only 18% in the HPNCs, providing evidence of hyperplasia. HAACs could be good surrogate indicators of carcinogen exposure, at least some of which may be related to colon carcinogenesis.
AB - Aberrant crypt foci, consisting of morphologically irregular crypts, are thought to be precancerous lesions for colorectal cancers. For analysis of individual crypts, F344 rats were administered weekly subcutaneous injections of 1,2-dimethylhydrazine ten times and sacrificed at experimental weeks 10 and 20 with 5-bromo-2′-deoxyuridine (BrdU) incorporation 1 h before the sacrifice. Isolated colonic crypts were classified into hexosaminidase-altered aberrant crypts (HAACs) and hexosaminidase-preserved normal-appearing crypts (HPNCs) and stereopaired images (tilt angle, 6°) were taken with a scanning electron microscope for three-dimensional analyses. While HPNCs showed symmetrical fission at the base, HAACs exhibited abnormal budding in the middle of the crypt body. At week 10, average BrdU labeled cells per crypt for DMH-treated HPNCs and HAACs were 4.9±1.0 and 18.7±2.2 (P<0.0001), respectively, while the value for non-treated control crypts was 14.7±0.8/crypt. BrdU-positive cell numbers per unit crypt length (100 μm) in HPNCs and HAACs were 1.75±0.37 and 5.99±0.70 (P<0.0001), respectively, while that for the control was 6.65±0.35 (P<0.02 vs. HAAC). At the 20-week time point, the numbers per crypt were 4.0±0.8, 10.1±1.6, and 27.4±2.4, respectively, the control value being significantly higher than the others (P<0.0001). The figures per unit length were 1.72±0.35, 2.92±0.42, and 13.39±1.11 (P<0.0001 vs. HAAC and HPNC), respectively. BrdU incorporating cells were distributed in the bottom third of the crypt columns in HAACs, but only 18% in the HPNCs, providing evidence of hyperplasia. HAACs could be good surrogate indicators of carcinogen exposure, at least some of which may be related to colon carcinogenesis.
UR - http://www.scopus.com/inward/record.url?scp=32544457095&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=32544457095&partnerID=8YFLogxK
U2 - 10.1016/j.etp.2005.10.004
DO - 10.1016/j.etp.2005.10.004
M3 - Article
C2 - 16414254
AN - SCOPUS:32544457095
SN - 0940-2993
VL - 57
SP - 283
EP - 289
JO - Experimental and Toxicologic Pathology
JF - Experimental and Toxicologic Pathology
IS - 4
ER -